SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Pfizer’s ELREXFIO Meets Primary Endpoint in Phase 3 Study

Pfizer said ELREXFIO outperformed standard regimens in the Phase 3 MagnetisMM-32 trial in relapsed or refractory multiple myeloma.

PFE
SquawkNews Desk 1 updates Updated Oct 27, 2026, 10:46 AM UTC

Story updates

10:46:22 AM UTC
SquawkNews
ELREXFIO monotherapy showed a statistically significant and clinically meaningful reduction in risk

Related stories

Polymarket Pauses Trading After $2.65 Million Exploit Polymarket said it placed its exchange in cancel-only mode and paused relayer actions while investigating a compromise of a third-party provider. More than $2.6 million was lost wi M impact | EQUITY | Oct 29, 2026, 07:01 PM UTC A. O. Smith Reports Third-Quarter 2026 Revenue of $940.5 Million Revenue fell 0.2% year over year to $940.5 million. Net income declined 4.3% to $126.3 million, while diluted EPS was $0.93 versus $0.94 a year earlier. M impact | EQUITY | Oct 29, 2026, 07:01 PM UTC Carrier Reports $2.59 Billion Third-Quarter Loss on $3.1 Billion Impairment Carrier Global reported third-quarter 2026 revenue of $6.26 billion, up 12.3% year over year, and diluted EPS loss of $3.16. A $3.1 billion goodwill impairment was tied to weaker E M impact | EQUITY | Oct 29, 2026, 07:01 PM UTC Microsoft Plans Bond Sale to Fund AI Buildout Microsoft said it is issuing debt in 10 parts, according to a filing. M impact | EQUITY | Oct 29, 2026, 07:00 PM UTC US session market picture: S&P 500 -0.62%, Nasdaq 100 -1.7%; EUR/USD +0.06%, WTI -0.64%, WBD leads volume US session market picture. US index futures: S and P futures is down 0.62 percent, Nasdaq futures is down 1.7 percent, Dow futures is down 0.61 percent and Russell futures is up 0. M impact | EQUITY | Oct 29, 2026, 07:00 PM UTC Mexedia Signs Equity Investment Agreement for Up to EUR 20 Million Mexedia signed a fixed-price equity investment agreement with Likan AG for up to EUR 20 million. M impact | EQUITY | Oct 29, 2026, 07:00 PM UTC